Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer

PURPOSE: Everolimus is a novel inhibitor of the mammalian target of rapamycin pathway, which is aberrantly activated in cancer cell. We conducted a phase I study of capecitabine plus everolimus (RAD001) in refractory gastric cancer patients. METHODS: Patients with metastatic gastric cancer and progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Taekyu, Lee, Jeeyun, Lee, Duk Joo, Lee, Ha Yeon, Han, Boram, Baek, Kyung Kee, Ahn, Hee Kyung, Lee, Su Jin, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Kim, Kyoung-Mee, Kang, Won Ki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123695/
https://www.ncbi.nlm.nih.gov/pubmed/21526353
http://dx.doi.org/10.1007/s00280-011-1653-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123695/
https://www.ncbi.nlm.nih.gov/pubmed/21526353
http://dx.doi.org/10.1007/s00280-011-1653-5

Ejemplares similares